Outpatient High-dose Methotrexate for Osteosarcoma: It’s Safe and Feasible, If You Want It
Authors:
- 1 July 2019
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 41 (5) , 394-398
Abstract
Background: High-dose methotrexate (HD MTX) is usually administered as an inpatient to those with osteosarcoma. We prospectively tested the safety and feasibility of administering HD MTX in the ambulatory setting. Materials and Methods: In this single arm prospective observational study, eligible patients had previously completed 2 courses of HD MTX as an inpatient. On study, patients received MTX in hospital, discharged home and returned for daily assessment. Criteria to determine safety and feasibility included: (1) parent compliance with home instructions, (2) pump functioning/failure, and/or (3) admission for toxicity/noncompliance. Outpatient therapy was deemed feasible if <25% courses resulted in study event. Patient satisfaction was assessed. Results: Six patients (median age, 13.5 y) with extremity osteosarcoma completed 35 courses of MTX. There were no study events—no hospitalizations or pump failures and all parents were compliant. The Data and Safety Committee concluded that with zero events in 35 courses, it was unlikely for outpatient MTX to be infeasible; study was thus terminated early. Participants reported value to stay out of hospital, permitted life to feel “more normal”; however, burden of daily commute to hospital was cited. Conclusions: The delivery of HD MTX is safe and feasible in patients with osteosarcoma.Keywords
This publication has 11 references indexed in Scilit:
- Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trialThe Lancet Oncology, 2016
- EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatmentAnnals of Oncology, 2014
- Ambulatory high‐dose methotrexate administration among pediatric osteosarcoma patients in an urban, underserved setting is feasible, safe, and cost‐effectivePediatric Blood & Cancer, 2010
- Methotrexate in Pediatric Osteosarcoma: Response and Toxicity in Relation to Genetic Polymorphisms and Dihydrofolate Reductase and Reduced Folate Carrier 1 ExpressionThe Journal of Pediatrics, 2009
- Clinical Drug Development for Childhood CancersClinical Pharmacology & Therapeutics, 2009
- Early Recognition of Renal Toxicity of High-dose Methotrexate TherapyJournal of Pediatric Hematology/Oncology, 2008
- The Memorial Sloan Kettering Cancer Center experience with outpatient administration of high dose methotrexate with leucovorin rescuePediatric Blood & Cancer, 2008
- Pediatric Home Chemotherapy: Infusing “Quality of Life”Journal of Pediatric Oncology Nursing, 2007
- Understanding and Managing Methotrexate NephrotoxicityThe Oncologist, 2006
- High‐dose methotrexate‐induced nephrotoxicity in patients with osteosarcomaCancer, 2004